Vericiguat (BAY1021189) (1.25 mg)

DRUG2 trials

Sponsors

Bayer

Conditions

Heart Failure

Phase 2

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

CompletedNCT01951625

BayerHeart Failure

Start: 2013-11-29End: 2015-06-09Updated: 2021-03-25

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

CompletedNCT01951638

BayerHeart Failure

Start: 2013-11-06End: 2015-09-16Updated: 2021-03-16

Related Papers

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.

2024-06-256 citations

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Clinical Pharmacokinetics2021-06-0426 citations

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.

2020-10-3043 citations

Evaluation of High-Sensitivity C-Reactive Protein and Uric Acid in Vericiguat-Treated Patients with Heart Failure with Reduced Ejection Fraction

European Journal of Heart Failure2020-03-2540 citations

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

JAMA2015-11-08372 citations